Issue 4 2020

6 Acquisition International - Issue 4 2020 Jan20482 Building a Better Future There are few things in the world that can unite people quite like the universal burden of cancer and neurodegenerative diseases. A company located on the German border near the Czech Republic remains wholly dedicated to the ongoing fight to erase these diseases forever. After its recognition as a Leading Innovator in AI-Based Personalised Medicine Solutions 2020 – Germany, we shine a light on the work of BioVariance GmbH in this latest issue of Acquisition International. hen someone becomes sick, physicians usually draw on the common range of medicines and pills. Paracetamol, Ibuprofen and other household drug brands will help most people overcome a headache or other minor aches. However, for the severe cases, such as cancer or neurodegenerative diseases, there is a rapid and strong need to find the right type of medicine that patients will potentially respond to. It is this need that the team of BioVariance have sought to address, by analysing complex biomedical and genetic data from patients to ensure they receive a personalized treatment. Founded in 2013 and headquartered in Waldsassen, Germany, BioVariance’s multidisciplinary team consisting of software W developers, biologists and data scientists develops innovative AI solutions for precision medicine in the healthcare, biotech and pharmaceutical sectors. In cooperation with oncological clinics, laboratories, pharmaceutical companies and physicians all over the country, BioVariance offers long-term monitoring of molecular changes in patients to predict the effectiveness, side effects and drug interactions of specific medications. The company also helps to determine the optimal medication and dosage for each patient individually. Achieving this level of information is not easy at all and requires the combination